Colom-Cadena M, Spires-Jones T, Zetterberg H, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alz Res Therapy 12, 21 (2020)
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease Read More »
PITTSBURGH, November 20, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that President & CEO Kenneth I. Moch will present an update on the Company’s lead Alzheimer’s candidate, Elayta™, at the 31st Annual Piper Jaffray
PITTSBURGH, September 10, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the company’s co-founder and chief science officer, Susan Catalano, Ph.D. will present an update on the Company’s lead candidate, Elayta™, at the 20th
PITTSBURGH, July 09, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced the receipt of a grant expected to total $3.3 million from the National Institute on Aging (NIA), part of the National Institutes of Health
Grundman M, Morgan R, Lickliterd JD, et al. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease. Alzheimers Dement (N Y). 2019 Jan 23; 5:20-26
PITTSBURGH, Nov 8, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that patient treatment has begun in the Phase 2 SHINE study of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. SHINE (Synaptic Health and Improvement of Neurological
PITTSBURGH, October 2, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a multiyear grant expected to total $16.6 million to
First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer’s Disease Research Unit and Yale PET Center PITTSBURGH, June 18, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today announced that patient dosing has begun in the SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition) study of
PITTSBURGH, June 5, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the first patient has been dosed in the SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients) Study of Elayta™ (CT1812), Cognition’s lead candidate for
PITTSBURGH, May 22, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the receipt of two multi-year grants from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) totaling $6.6 million. These
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
